We read with great interest the brief report by Prof. Ray et al on the association between uric acid– lowering therapies and gout incidence among patients treated with bempedoic acid in the CLEAR (Cholesterol LowEring via bempedoic acid, an ACLinhibiting Regimen) Outcomes trial.1 The authors are to be commended for addressing an often-overlooked metabolic aspect of bempedoic acid therapy and for providing valuable insights into the management of hyperuricemia in this population. We would like to offer a few considerations that may further contextualize and expand the clinical interpretation of these findings
Fogacci, F., Borghi, C., Cicero, A.F.G. (2025). Beyond the Numbers: Reframing Uric Acid Elevations in Bempedoic Acid Therapy. JACC. ADVANCES, 5(1), 1-2 [10.1016/j.jacadv.2025.102482].
Beyond the Numbers: Reframing Uric Acid Elevations in Bempedoic Acid Therapy
Borghi CSecondo
Writing – Review & Editing
;Cicero AFGUltimo
Conceptualization
2025
Abstract
We read with great interest the brief report by Prof. Ray et al on the association between uric acid– lowering therapies and gout incidence among patients treated with bempedoic acid in the CLEAR (Cholesterol LowEring via bempedoic acid, an ACLinhibiting Regimen) Outcomes trial.1 The authors are to be commended for addressing an often-overlooked metabolic aspect of bempedoic acid therapy and for providing valuable insights into the management of hyperuricemia in this population. We would like to offer a few considerations that may further contextualize and expand the clinical interpretation of these findings| File | Dimensione | Formato | |
|---|---|---|---|
|
Fogacci F_Beyond the Numbers_JACC advances.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale / Version Of Record
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione
172.73 kB
Formato
Adobe PDF
|
172.73 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
